Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
The efficacy of these drugs has been proved through robust multi-centre clinical trials
Ministry of Ayush is launching a massive nationwide campaign to distribute its proven polyherbal Ayurvedic drugs AYUSH 64 and Sidha drug Kabasura Kudineer for the benefit of the vast majority of out of hospital COVID-19 patients.
The efficacy of these drugs has been proved through robust multi-centre clinical trials. The multi-stakeholder campaign being launched by Kiren Rijiju, Minister of State for Youth Affairs and Sports and Minister of Ayush will ensure that medicines reach the needy in a transparent and efficient manner.
The Ministry of Ayush- Council of Scientific and Industrial Research (CSIR) collaboration has recently completed a robust multi-center clinical trial to evaluate the safety and efficacy of AYUSH 64 in the management of mild to moderate COVID-19 patients.
AYUSH-64 is recommended in National Clinical Management Protocol based on Ayurveda and Yoga which is vetted by the National Task Force on COVID Management of ICMR and Guidelines for Ayurveda Practitioners for COVID-19 Patients in Home Isolation. Kabasura Kudineer is included in Guidelines for Siddha Practitioners for COVID-19, Ministry of Ayush Government of India.
Based on the encouraging results of AYUSH-64 and Kabasura Kudineer in the management of asymptomatic, mild to moderate COVID-19 as an adjunct to Standard care, the Ministry of Ayush is launching this nationwide campaign for the distribution of AYUSH-64 and Kabaasur Kudineer so that the COVID -19 patients in home isolation may be benefitted with Ayush systems of medicines.